Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4D | Q08499 | 14/20 | 0.59 |
| ▸ | PDE4A | P27815 | 7/20 | 0.58 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.43 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15071014 | 0.89 | PDE4D (0.56) | PDE4DPDE4APDE4BPDE4C | |
| SCHEMBL10165203 | 0.86 | PDE4D (0.60) | PDE4DPDE4A | |
| SCHEMBL15060224 | 0.86 | PDE4D (0.60) | PDE4DPDE4APDE4BPDE4C | |
| SCHEMBL508221 | 0.85 | PDE4D (0.59) | PDE4DPDE4A | |
| SCHEMBL508339 | 0.80 | PDE4D (0.46) | PDE4DPDE4A | |
| SCHEMBL16339826 | 0.79 | PDE4D (0.54) | PDE4DPDE4A | |
| SCHEMBL510067 | 0.77 | PDE4D (0.80) | PDE4D | |
| SCHEMBL3469123 | 0.77 | PDE4D (0.65) | PDE4DPDE4A | |
| SCHEMBL509664 | 0.76 | PDE4D (0.76) | PDE4D | |
| SCHEMBL3469295 | 0.75 | PDE4D (0.76) | PDE4DPDE4APDE4BPDE4C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3013827-A1 | BROMODOMAIN INHIBITORS | AbbVie Inc. (US) | 2016-05-04 | — | — | EP | claimed |
| EP-3013828-A1 | BROMODOMAIN INHIBITORS | AbbVie Inc. (US) | 2016-05-04 | — | — | EP | claimed |
| WO-2014206345-A1 | BROMODOMAIN INHIBITORS | ABBVIE INC. (US) | 2014-12-31 | — | — | WO | claimed |
| WO-2014206903-A1 | METHODS FOR THE PREPARATION OF SUBSTITUTED [1,2,4]TRIAZOLO[1,5-a]PYRIDINES | LEO PHARMA A/S (DK) | 2014-12-31 | — | — | WO | claimed |
| WO-2014206150-A1 | BROMODOMAIN INHIBITORS | ABBVIE INC. (US) | 2014-12-31 | — | — | WO | claimed |
| EP-2794603-B1 | [1,2,4]TRIAZOLOPYRIDINES AND THEIR USE AS PHOSPODIESTERASE INHIBITORS | LEO PHARMA AS (DK) | 2016-06-15 | — | — | EP | disclosed |
| EP-2794603-B1 | [1,2,4]TRIAZOLOPYRIDINES AND THEIR USE AS PHOSPODIESTERASE INHIBITORS | LEO PHARMA AS (DK) | 2016-06-15 | — | — | EP | disclosed |
| EP-3013828-A1 | BROMODOMAIN INHIBITORS | AbbVie Inc. (US) | 2016-05-04 | — | — | EP | disclosed |
| EP-3013827-A1 | BROMODOMAIN INHIBITORS | AbbVie Inc. (US) | 2016-05-04 | — | — | EP | disclosed |
| US-9181248-B2 | [1,2,4]triazolopyridines and their use as phosphodiesterase inhibitors | LEO PHARMA A/S (DK) | 2015-11-10 | — | — | US | disclosed |
| US-9181248-B2 | [1,2,4]triazolopyridines and their use as phosphodiesterase inhibitors | LEO PHARMA A/S (DK) | 2015-11-10 | — | — | US | disclosed |
| US-9181248-B2 | [1,2,4]triazolopyridines and their use as phosphodiesterase inhibitors | LEO PHARMA A/S (DK) | 2015-11-10 | — | — | US | disclosed |
| WO-2014206345-A1 | BROMODOMAIN INHIBITORS | ABBVIE INC. (US) | 2014-12-31 | — | — | WO | disclosed |
| WO-2014206903-A1 | METHODS FOR THE PREPARATION OF SUBSTITUTED [1,2,4]TRIAZOLO[1,5-a]PYRIDINES | LEO PHARMA A/S (DK) | 2014-12-31 | — | — | WO | disclosed |
| US-20140329853-A1 | [1,2,4]TRIAZOLOPYRIDINES AND THEIR USE AS PHOSPHODIESTERASE INHIBITORS | UNION therapeutics A/S (DK) | 2014-11-06 | — | — | US | disclosed |
| US-20140329853-A1 | [1,2,4]TRIAZOLOPYRIDINES AND THEIR USE AS PHOSPHODIESTERASE INHIBITORS | UNION therapeutics A/S (DK) | 2014-11-06 | — | — | US | disclosed |
| US-20140329853-A1 | [1,2,4]TRIAZOLOPYRIDINES AND THEIR USE AS PHOSPHODIESTERASE INHIBITORS | UNION therapeutics A/S (DK) | 2014-11-06 | — | — | US | disclosed |
| EP-2794603-A1 | [1,2,4]TRIAZOLOPYRIDINES AND THEIR USE AS PHOSPODIESTERASE INHIBITORS | Leo Pharma A/S (DK) | 2014-10-29 | — | — | EP | disclosed |
| WO-2013092739-A1 | [1,2,4]TRIAZOLOPYRIDINES AND THEIR USE AS PHOSPODIESTERASE INHIBITORS | LEO PHARMA A/S (DK) | 2013-06-27 | — | — | WO | disclosed |
| WO-2013092739-A1 | [1,2,4]TRIAZOLOPYRIDINES AND THEIR USE AS PHOSPODIESTERASE INHIBITORS | LEO PHARMA A/S (DK) | 2013-06-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140329853-A1 | [1,2,4]TRIAZOLOPYRIDINES AND THEIR USE AS PHOSPHODIESTERASE INHIBITORS | PDE4A, PDE3A, PDE2A | PDE4D 7/4885PDE4A 1/4885PDE4B 6/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.